Cargando…

Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin

BACKGROUND: Prescription of second-generation antipsychotic drugs (SGAs) to childhood/adolescent has exponentially increased in recent years, which was associated with the greater risk of significant weight gain and dyslipidemia. Statin is considered a potential preventive and treatment approach for...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xuemei, Feng, Xiyu, Deng, Chao, Liu, Lu, Zeng, Yanping, Hu, Chang-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325271/
https://www.ncbi.nlm.nih.gov/pubmed/32605639
http://dx.doi.org/10.1186/s40360-020-00427-0
_version_ 1783552118473359360
author Liu, Xuemei
Feng, Xiyu
Deng, Chao
Liu, Lu
Zeng, Yanping
Hu, Chang-Hua
author_facet Liu, Xuemei
Feng, Xiyu
Deng, Chao
Liu, Lu
Zeng, Yanping
Hu, Chang-Hua
author_sort Liu, Xuemei
collection PubMed
description BACKGROUND: Prescription of second-generation antipsychotic drugs (SGAs) to childhood/adolescent has exponentially increased in recent years, which was associated with the greater risk of significant weight gain and dyslipidemia. Statin is considered a potential preventive and treatment approach for reducing SGA-induced weight gain and dyslipidemia in schizophrenia patients. However, the effect of statin treatment in children and adolescents with SGA-induced dyslipidemia is not clearly demonstrated. METHODS: To investigate the efficacy of statin interventions for reversing SGA-induced dyslipidemia, young Sprague Dawley rats were treated orally with either olanzapine (1.0 mg/kg, t.i.d.), simvastatin (3.0 mg/kg, t.i.d.), olanzapine plus simvastatin (O + S), or vehicle (control) for 5 weeks. RESULTS: Olanzapine treatment increased weight gain, food intake and feeding efficiency compared to the control, while O + S co-treatment significantly reversed body weight gain but without significant effects on food intake. Moreover, olanzapine treatment induced a slight but significant reduction in body temperature, with a decrease in locomotor activity. Fasting plasma glucose, triglycerides (TG), and total cholesterol (TC) levels were markedly elevated in the olanzapine-only group, whereas O + S co-treatment significantly ameliorated these changes. Pronounced activation of lipogenic gene expression in the liver and down-regulated expression of uncoupling protein-1 (UCP1) and peroxisome-proliferator-activated receptor-γ co-activator-1α (PGC-1α) in brown adipose tissue (BAT) was observed in the olanzapine-only group. Interestingly, these protein changes could be reversed by co-treatment with O + B. CONCLUSIONS: Simvastatin is effective in ameliorating TC and TG elevated by olanzapine. Modulation of BAT activity by statins could be a partial mechanism in reducing metabolic side effects caused by SGAs in child and adolescent patients. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7325271
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73252712020-06-30 Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin Liu, Xuemei Feng, Xiyu Deng, Chao Liu, Lu Zeng, Yanping Hu, Chang-Hua BMC Pharmacol Toxicol Research Article BACKGROUND: Prescription of second-generation antipsychotic drugs (SGAs) to childhood/adolescent has exponentially increased in recent years, which was associated with the greater risk of significant weight gain and dyslipidemia. Statin is considered a potential preventive and treatment approach for reducing SGA-induced weight gain and dyslipidemia in schizophrenia patients. However, the effect of statin treatment in children and adolescents with SGA-induced dyslipidemia is not clearly demonstrated. METHODS: To investigate the efficacy of statin interventions for reversing SGA-induced dyslipidemia, young Sprague Dawley rats were treated orally with either olanzapine (1.0 mg/kg, t.i.d.), simvastatin (3.0 mg/kg, t.i.d.), olanzapine plus simvastatin (O + S), or vehicle (control) for 5 weeks. RESULTS: Olanzapine treatment increased weight gain, food intake and feeding efficiency compared to the control, while O + S co-treatment significantly reversed body weight gain but without significant effects on food intake. Moreover, olanzapine treatment induced a slight but significant reduction in body temperature, with a decrease in locomotor activity. Fasting plasma glucose, triglycerides (TG), and total cholesterol (TC) levels were markedly elevated in the olanzapine-only group, whereas O + S co-treatment significantly ameliorated these changes. Pronounced activation of lipogenic gene expression in the liver and down-regulated expression of uncoupling protein-1 (UCP1) and peroxisome-proliferator-activated receptor-γ co-activator-1α (PGC-1α) in brown adipose tissue (BAT) was observed in the olanzapine-only group. Interestingly, these protein changes could be reversed by co-treatment with O + B. CONCLUSIONS: Simvastatin is effective in ameliorating TC and TG elevated by olanzapine. Modulation of BAT activity by statins could be a partial mechanism in reducing metabolic side effects caused by SGAs in child and adolescent patients. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2020-06-30 /pmc/articles/PMC7325271/ /pubmed/32605639 http://dx.doi.org/10.1186/s40360-020-00427-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Liu, Xuemei
Feng, Xiyu
Deng, Chao
Liu, Lu
Zeng, Yanping
Hu, Chang-Hua
Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
title Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
title_full Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
title_fullStr Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
title_full_unstemmed Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
title_short Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
title_sort brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325271/
https://www.ncbi.nlm.nih.gov/pubmed/32605639
http://dx.doi.org/10.1186/s40360-020-00427-0
work_keys_str_mv AT liuxuemei brownadiposetissueactivityismodulatedinolanzapinetreatedyoungratsbysimvastatin
AT fengxiyu brownadiposetissueactivityismodulatedinolanzapinetreatedyoungratsbysimvastatin
AT dengchao brownadiposetissueactivityismodulatedinolanzapinetreatedyoungratsbysimvastatin
AT liulu brownadiposetissueactivityismodulatedinolanzapinetreatedyoungratsbysimvastatin
AT zengyanping brownadiposetissueactivityismodulatedinolanzapinetreatedyoungratsbysimvastatin
AT huchanghua brownadiposetissueactivityismodulatedinolanzapinetreatedyoungratsbysimvastatin